Slowing Biopharmaceuticals Puts A Dent In Sandoz’ Sales

 
• By Aidan Fry

Slower sales growth by its Biopharmaceuticals unit amid competitive pressures in the US, combined with weakness in its Retail Generics and Anti-Infectives franchises, led Sandoz to report an overall 8% sales slide in the first quarter of this year. 

Snail
Weakness in the US has slowed the rate of growth of Sandoz' Biopharmaceuticals business unit • Source: Shutterstock

More from Earnings

More from Business